/GRCL

GRCL Stock - Gracell Biotechnologies Inc.

Q: What is the analyst price target for GRCL?

Analyst price target information is not currently available for GRCL.

Q: What is GRCL's market cap?

Market capitalization information is not currently available for GRCL.

Healthcare|Biotechnology|NASDAQ

$10.25+0.05%

+$0.01 (+0.05%) • Feb 21

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-41.5%upside

Target: $6.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GRCL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.34

52W High$10.44

52W Low$1.40

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	$366,000	N/A	N/A	N/A
Gross Profit	N/A	$366,000	N/A	N/A	N/A
Gross Margin	N/A	100.0%	N/A	N/A	N/A
Operating Income	$-624,658,000	$-463,573,000	$-214,396,000	$-146,580,000	$-62,504,000
Net Income	$-607,509,000	$-465,880,000	$-197,161,000	$-132,176,000	$-60,793,000
Net Margin	N/A	-127289.6%	N/A	N/A	N/A
EPS	$-44.85	$-35.40	$-15.05	$-33.35	$-15.35

Company Overview

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

4 Bullish0 Neutral/Bearish

Price Targets

$11

Average Target

↑ 9.3% Upside

Now

Low

$11

Average

$20

High

Based on 5 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 27th 2023	Evercore ISI	Initiation	Outperform	-
October 19th 2023	Stifel	Initiation	Buy	$11
March 27th 2023	Wells Fargo	Resumed	Overweight	$7
December 8th 2022	H.C. Wainwright	Initiation	Buy	$6
September 22nd 2022	Citigroup	Initiation	Buy	$12
August 18th 2022	Wells Fargo	Resumed	Overweight	-
June 1st 2022	Cantor Fitzgerald	Initiation	Overweight	$20

Earnings History & Surprises

GRCL

Beat Rate

38%

Last 13 quarters

Avg Surprise

-108.9%

EPS vs Estimate

Beats / Misses

5/7

1 met exactly

Latest EPS

$-0.30

Q1 2024

EPS Surprise History

Q2 22

-362.5%

$-0.37vs$-0.08

Q3 22

-300.0%

$-0.32vs$-0.08

Q4 22

-300.0%

$-0.36vs$-0.09

Q1 23

+30.2%

$-0.30vs$-0.43

Q2 23

0.0%

$-0.35vs$-0.35

Q3 23

+18.9%

$-0.30vs$-0.37

Q4 23

+61.5%

$-0.10vs$-0.26

Q1 24

-114.3%

$-0.30vs$-0.14

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 12, 2024	—	—	—	—
Q2 2024	May 13, 2024	—	—	—	—
Q1 2024	Mar 11, 2024	$-0.14	$-0.30	-114.3%	✗ MISS
Q4 2023	Nov 13, 2023	$-0.26	$-0.10	+61.5%	✓ BEAT
Q3 2023	Aug 14, 2023	$-0.37	$-0.30	+18.9%	✓ BEAT
Q2 2023	May 15, 2023	$-0.35	$-0.35	0.0%	= MET
Q1 2023	Mar 13, 2023	$-0.43	$-0.30	+30.2%	✓ BEAT
Q4 2022	Nov 14, 2022	$-0.09	$-0.36	-300.0%	✗ MISS
Q3 2022	Aug 15, 2022	$-0.08	$-0.32	-300.0%	✗ MISS
Q2 2022	May 16, 2022	$-0.08	$-0.37	-362.5%	✗ MISS
Q1 2022	Mar 14, 2022	$-0.38	$-0.30	+21.1%	✓ BEAT
Q4 2021	Nov 15, 2021	$-0.12	$-0.30	-150.0%	✗ MISS
Q3 2021	Aug 17, 2021	$-0.05	$-0.22	-340.0%	✗ MISS
Q2 2021	May 17, 2021	$-0.21	$-0.25	-19.0%	✗ MISS
Q1 2021	Mar 9, 2021	$-0.26	$-0.16	+38.5%	✓ BEAT
Q1 2021	Jan 8, 2021	—	$-0.11	—	—
Q2 2020	Jun 30, 2020	—	$-0.33	—	—
Q1 2020	Mar 31, 2020	—	$-0.23	—	—
Q4 2019	Dec 31, 2019	—	$-0.31	—	—

Frequently Asked Questions about GRCL

What is GRCL's current stock price?

Gracell Biotechnologies Inc. (GRCL) is currently trading at $10.25 per share. The stock has moved +0.05% today.

What is the analyst price target for GRCL?

The average analyst price target for GRCL is $6.00, based on 1 analyst.

What sector is Gracell Biotechnologies Inc. in?

Gracell Biotechnologies Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is GRCL's market cap?

Gracell Biotechnologies Inc. has a market capitalization of $0.99 billion, making it a small-cap company.

Does GRCL pay dividends?

No, Gracell Biotechnologies Inc. does not currently pay a dividend to shareholders.